Five captopril tentative ANDAs must await Capoten extension decision under GATT, Royce says.
FIVE GENERIC CAPOTEN TENTATIVE ANDA APPROVALS MUST AWAIT FDA GATT POLICY that could extend the patent expiration date for Bristol-Myers Squibb's ACE inhibitor Capoten from Aug. 8 to February or December 1996, Royce Labs contends. Royce received tentative ANDA approval for captopril tablets March 31. Mylan and Novopharm received tentative approvals for the drug on March 22. Ciba's Geneva generics operations received the first tentative approval for captopril on Jan. 30. However, BMS' Apothecon generics operations gained full ANDA approval March 31.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth